Skip to search formSkip to main contentSkip to account menu

dasatinib 140 MG Oral Tablet [Sprycel]

Known as: SPRYCEL 140 MG Oral Tablet 
National Institutes of Health

Related topics

Related topics

12 relations
Croscarmellose SodiumLactose MonohydrateMagnesium stearateOral Tablet

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Bleeding Diathesis in Patients (pts) with Chronic Myelogenous Leukemia Receiving Dasatinib Therapy.
Dasatinib (Sprycel®, Bristol-Myers Squibb) is an oral potent ATP-competitive multikinase inhibitor active against BCR-ABL and SRC… 
2006
2006
Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START…
Dasatinib (SPRYCEL®, formerly BMS-354825) is a novel, oral, multi-targeted kinase inhibitor that induces complete hematologic and… 
2006
2006
Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study…
Pts with CML resistant to im have few therapeutic options. A growing body of evidence suggests that treatment outcomes can be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)